Insilico Medicine
The deal grants Lilly exclusive global rights to use Insilico's Pharma.AI platform for drug discovery and development across multiple therapeutic areas.
The funds will be used to advance Insilico's drug pipeline and lab, which automates the research and development process, and refine its AI-enabled models and algorithms.